GSK’s malaria vaccine gets WHO okay for mass rolloutThe WHO has given a green light to widespread use of GlaxoSmithKline’s malaria vaccine in Africa, in what Share XGSK’s malaria vaccine gets WHO okay for mass rollouthttps://pharmaphorum.com/news/gsks-malaria-vaccine-gets-who-okay-for-mass-rollout/
GSK bails on $4.2bn partnership with Merck on cancer drugGlaxoSmithKline has ended its collaboration with Germany’s Merck KGaA’s cancer treatment bintrafusp alfa, after a trio of failed Share XGSK bails on $4.2bn partnership with Merck on cancer drughttps://pharmaphorum.com/news/gsk-bails-on-4-2bn-partnership-with-merck-on-cancer-drug/
Sanofi abandons mRNA COVID jab, despite positive trialSanofi has said that it won’t develop its mRNA-based vaccine for COVID-19 any further, even though it seemed Share XSanofi abandons mRNA COVID jab, despite positive trialhttps://pharmaphorum.com/news/sanofi-abandons-mrna-covid-jab-despite-positive-trial/
Second hedge fund applies pressure on GSK after taking stakeActivist hedge fund Bluebell Capital Partners has joined Elliott Investment in taking a stake in GlaxoSmithKline and pushing Share XSecond hedge fund applies pressure on GSK after taking stakehttps://pharmaphorum.com/news/second-hedge-fund-applies-pressure-on-gsk-after-taking-stake/
Pfizer raises pressure on GSK, J&J with late-stage RSV vaccine trialPfizer has vaulted ahead with its respiratory syncytial virus (RSV) vaccine, closing the gap with GlaxoSmithKline and Johnson Share XPfizer raises pressure on GSK, J&J with late-stage RSV vaccine trialhttps://pharmaphorum.com/news/pfizer-raises-pressure-on-gsk-jj-with-late-stage-rsv-vaccine-trial/
GSK takes SK bio-partnered COVID jab into phase 3As a top vaccine maker, GlaxoSmithKline has been a laggard in the COVID-19 vaccine race, but has put Share XGSK takes SK bio-partnered COVID jab into phase 3https://pharmaphorum.com/news/gsk-takes-sk-bio-partnered-covid-jab-into-phase-3/
Third strike for GSK/Merck as bintrafusp alfa flubs againGlaxoSmithKline’s big gamble on Merck KGaA’s bintrafusp alfa has gone from bad to worse, after the drug failed Share XThird strike for GSK/Merck as bintrafusp alfa flubs againhttps://pharmaphorum.com/news/third-strike-for-gsk-merck-cancer-alliance-as-bintrafusp-alfa-flubs-again/
After FDA snub, EMA backs FibroGen, Astellas’ roxadustatThe EU regulator has approved FibroGen and Astellas Evrenzo for adults with anaemia caused by chronic kidney disease Share XAfter FDA snub, EMA backs FibroGen, Astellas’ roxadustathttps://pharmaphorum.com/news/after-fda-snub-ema-backs-fibrogen-astellas-roxadustat/
GSK claims broader ’tissue-agnostic’ label for PD-1 drug JemperliThe FDA has approved GlaxoSmithKline’s latecomer PD-1 inhibitor Jemperli for a second use that will significantly extend the Share XGSK claims broader ’tissue-agnostic’ label for PD-1 drug Jemperlihttps://pharmaphorum.com/news/gsk-claims-broader-tissue-agnostic-label-for-pd-1-drug-jemperli/
